Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer Institute

增加对温希普癌症研究所 NCI 资助的临床试验的参与

• 批准号: 10721093
• 负责人: Jonathon B. Cohen
• 金额: $ 15.66万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-22 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10721093
• 关键词: Address; American College of Radiology Imaging Network; Award; Cancer Center; Clinic; Clinical; Clinical Trials; Collaborations; Communication; Communities; Community Outreach; Conduct Clinical Trials; Country; Data; Development; Disease; Early Therapeutic-Clinical Trials Network; Eastern Cooperative Oncology Group; Enrollment; Ensure; Funding; Future; Growth; Home; Improve Access; Institution; Lead; Leadership; Lymphoma; Malignant Neoplasms; Modality; Monitor; National Clinical Trials Network; Oncologist; Patient-Focused Outcomes; Patients; Persons; Positioning Attribute; Research; Research Personnel; Resources; Role; Safety; Series; Site; Specialist; Therapeutic Studies; Tumor Expansion; Universities; career; cohort; community engagement; experience; improved; improved outcome; innovation; interest; metropolitan; next generation; participant enrollment; programs; skills; standard of care; success; virtual; working group; Address; American College of Radiology Imaging Network; Award; Cancer Center; Clinic; Clinical; Clinical Trials; Collaborations; Communication; Communities; Community Outreach; Conduct Clinical Trials; Country; Data; Development; Disease; Early Therapeutic-Clinical Trials Network; Eastern Cooperative Oncology Group; Enrollment; Ensure; Funding; Future; Growth; Home; Improve Access; Institution; Lead; Leadership; Lymphoma; Malignant Neoplasms; Modality; Monitor; National Clinical Trials Network; Oncologist; Patient-Focused Outcomes; Patients; Persons; Positioning Attribute; Research; Research Personnel; Resources; Role; Safety; Series; Site; Specialist; Therapeutic Studies; Tumor Expansion; Universities; career; cohort; community engagement; experience; improved; improved outcome; innovation; interest; metropolitan; next generation; participant enrollment; programs; skills; standard of care; success; virtual; working group

PROJECT SUMMARY/ABSTRACT I have devoted my career to the improvement of outcomes for patients with lymphoma and have utilized my expertise to improve clinical trial conduct at my home institution and nationally. I have developed a sincere commitment to the success of NCI-funded clinical trials, which often address the most critical clinical questions and which consistently challenge the standard of care in order to improve patient outcomes nationwide. Winship Cancer Institute of Emory University is a National Clinical Trial Network Lead Academic Participating Site and boasts a robust clinical trial portfolio, enrolling roughly 1000 patients per year to therapeutic studies at multiple sites throughout metropolitan Atlanta. I am the co-director of the lymphoma disease program, leader of the lymphoma treatment modality working group, and chair of the Data Safety Monitoring Committee. In these roles I can impact clinical trials in my clinic and throughout the Cancer Center. I have also assumed leadership of trials through the ECOG-ACRIN lymphoma committee (PrE0404, A051201), have recently been appointed to represent ECOG-ACRIN’s lymphoma committee on a Real World Evidence Working Group, and am the co-chair of the lymphoma disease specific working group for Winship’s ETCTN consortium. As a result, I am well- positioned to significantly impact of the success of NCI-funded studies. I will utilize the resources of the R50 Research Specialist Award to improve NCI-funded clinical trials through improved access and accrual to NCTN and ETCTN trials in Atlanta and the state of Georgia by strengthening existing collaborations with oncologists throughout the state in association with Winship’s Office of Community Outreach and Engagement. This will include expansion of tumor boards and national programming, 1:1 in person and virtual communication with colleagues, and facilitation of opportunities to enroll patients in NCTN studies closer to their home communities. I will continue to develop a pipeline of junior investigators and trainees nationwide who are interested in clinical trials and will ensure they have access to NCTN and ETCTN support to support development of their own concepts. I will develop the next series of trials by utilizing my experience as a leader in Real World Evidence cohorts, both within ECOG-ACRIN and with colleagues throughout the country. I will continue growth of the NCTN and ETCTN at Winship and will ensure that colleagues continue to have innovative studies to which to enroll patients and have the skills needed to develop their own projects based on current and future clinical needs.

项目摘要/摘要 我致力于改善淋巴瘤患者的结局，并利用了我的 在我的家庭机构和全国范围内改善临床试验的专业知识。我已经发表了真诚的 致力于NCI资助的临床试验的成功，该试验通常解决最关键的临床问题 并始终如一地挑战护理标准，以改善全国患者的结果。胜利 埃默里大学癌症研究所是国家临床试验网络领导学术参与地点， 拥有强大的临床试验组合，每年约有1000名患者接受多个治疗研究 整个亚特兰大大都会的地点。我是淋巴瘤疾病计划的联合导演， 淋巴瘤治疗方式工作组和数据安全监测委员会主席。在这些角色中 我可以影响诊所和整个癌症中心的临床试验。我也以试验的领导 通过ECOG-acrin淋巴瘤委员会（PRE0404，A051201），最近被任命为 代表ECOG-ACRIN的淋巴瘤委员会是现实世界证据工作组，是联合主席 Winship的ETCTN财团的淋巴瘤疾病特异性工作组。结果，我很好 定位是显着影响NCI资助的研究成功。我将利用R50的资源 研究专家奖，旨在通过提高NCTN的访问和准确性来改善NCI资助的临床试验 通过加强与肿瘤学家的现有合作，亚特兰大和佐治亚州的ETCTN试验 在整个州，与Winship的社区外展和参与办公室联合。这会 包括扩展肿瘤板和国家节目，亲自1：1和与虚拟沟通 同事，以及将患者参与NCTN研究的机会，更接近其家庭社区。 我将在全国范围内开发一个对临床感兴趣的初级调查员和实习生的管道 试验，并将确保他们能够获得NCTN和ETCTN支持以支持自己的发展 概念。我将利用我作为现实世界证据的领导者的经验来开发下一系列的试验 在ECOG-ACRIN内部和全国各地的同事中，同伙。我将继续增长 NCTN和ETCTN在Winship中，将确保同事继续进行创新的研究 注册患者，并具有根据当前和未来的临床发展自己项目所需的技能 需要。